Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese RA market boasts six biologics: the TNF-α inhibitors etanercept (Amgen’s Enbrel, biosimilars), adalimumab (AbbVie’s Humira), infliximab (Janssen’s Remicade), and golimumab (Janssen’s Simponi); theIL-6 inhibitor tocilizumab (Roche’s Actemra); the B-cell modulator rituximab (Roche’s MabThera, biosimilars); and the oral JAK inhibitor Xeljanz (tofacitinib). The TNF-α inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs, and other biologics and the JAK inhibitor tofacitinib largely compete for use in TNF-α-inhibitor-refractory patients. With the expected launch of additional targeted therapies, in addition to the availability of the cost-effective biosimilars of marketed TNF-α inhibitors during the forecast period, the Chinese RA market will witness fierce competition and increasing challenges to gain market uptake.
- How large is China’s drug-treatable RA population and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s RA market and why? What are interviewed experts’ insights on current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations of key therapies in the RA pipeline in China? What sales/uptake could they secure in RA? What are interviewed experts’ opinion on the key emerging therapies?
- What are the key drivers and constraints in the China RA market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading rheumatologists, supported by survey data collected for this and other DRG research.
Diagnosed prevalence of RA by disease stage. Clinically and market relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key RA therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 8 drugs; Phase II: 2 drugs; Coverage of select early-phase products.